FORM 7

MONTHLY PROGRESS REPORT

Name of CSE Issuer: NAMESILO TECHNOLOGIES CORP. (the "Issuer")

Trading Symbol: URL

Number of Outstanding Listed Securities: 91,585,648

Date: October 3, 2023

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

NameSilo Technologies Corp. (the "Issuer") invests its capital in companies and opportunities which management believe are undervalued and have potential for significant appreciation. The Issuer makes investments in both public and private markets and focuses on opportunities in a wide variety of industries excluding the resource and resource service sectors.

Throughout the month of September the Issuer remained in contact with management of ImmunoPrecise Antibodies Ltd. ("ImmunoPrecise"), and Pioneering Technologies Corp. ("Pioneering").

Upon completion of its acquisition of NameSilo, LLC ("NameSilo"), the Issuer is now a provider of domain name registration services and marketplace services for the buying and selling of domain names.

2. Provide a general overview and discussion of the activities of management.

Management was actively engaged in all general administrative and sundry duties of the Issuer, and focused on creating strategic relationships. The Issuer also remained in contact with management of ImmunoPrecise Antibodies Ltd. ("ImmunoPrecise"), and Pioneering Technologies Corp. ("Pioneering").

On September 22, 2023, the Issuer announced its intention to initiate a normal course issuer bid ("NCIB") through the facilities of the CSE. Under the NCIB, the Issuer intends to acquire up to 4,500,000 common shares in the capital of the Issuer, representing approximately 4.91% of its issued and outstanding common shares. The NCIB will commence on September 26, 2023 and end no later than September 26, 2024.

The Issuer may terminate the NCIB earlier if it feels it is appropriate to do so. The Issuer has appointed Canaccord Genuity Corp. to conduct the NCIB. All Shares acquired will be returned to treasury and cancelled. The Issuer is commencing the NCIB because it believes that the current market price of its common shares may not fully reflect the underlying value of the Issuer's business and future prospects.

- Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
 - No new products or services were developed to completion or offered in the current reporting month.
- 4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
 - Not applicable.
- Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
 - Issuer did not enter into any new business relationships during the month of September 2023.
- 6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
 - Not applicable.
- 7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
 - On occasion, the Issuer will also acquire or dispose of publicly traded shares of companies. These transactions are disclosed in the Issuer's quarterly financial statements.
- 8. Describe the acquisition of new customers or loss of customers.

Since its acquisition of NameSilo on August 1, 2018, the Issuer has continued to acquire new customers for its domain name registration and management services.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

- 11. Report on any labour disputes and resolutions of those disputes if applicable.

 Not applicable.
- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

 Not applicable.
- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

During the reporting month, no indebtedness was incurred or repaid outside of the normal course of operations.

- 14. Provide details of any securities issued and options or warrants granted.
 - No common shares, stock options or share purchase warrants were issued by the Issuer or exercised in the reporting month.
- 15. Provide details of any loans to or by Related Persons.
 - There were no loans to or by Related Persons in the reporting month, although management is owed funds from time to time as a result of the accrual of salary for cash flow management purposes.
- 16. Provide details of any changes in directors, officers or committee members.
 - There were no changes in directors, officers or committee members in the reporting month.
- 17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
 - During the current reporting month, there continued to be a global pandemic outbreak of COVID-19. The actual and threatened spread of the virus globally has had a material adverse effect on the global economy and specifically, the regional economies in which the Company operates. Although the Issuer is presently not aware of any confirmed cases of COVID-19 among its management and employees, it may result in modest delays in the course of

prices of the Issuer's shares and its ability to raise among others, could have a significant impact on the	new capital. These factors, Issuer's operations.

Certificate Of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
- 4. All of the information in this Form 7 Monthly Progress Report is true.

Dated October 3, 2023 .	
	Paul Andreola Name of Director or Senior Officer
	(s) Paul Andreola Signature
	President, CEO and Director

Issuer Details	For Month End	Date of Report
Name of Issuer		YY/MM/DD
NAMESILO TECHNOLOGIES CORP.	September, 2023	2023/10/03
Issuer Address #1052 – 409 Granville Street		
City/Province/Postal Code Vancouver, British Columbia V6C 1T2	Issuer Fax No. (604) 683-7589	Issuer Telephone No. (604) 644-0072
Contact Name	Contact Position	Contact Telephone No.
Paul Andreola	President, CEO and Director	(604) 644-0072
Contact Email Address	Web Site Address	
Paul@brisio.com	http://brisio.com/home/	